Case ID 103230037621

Patient Name VINEETA DHILLON

Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:09 Hrs
Sample Processed At CORE GGN

TEST NAME
BLOOD GROUP ABO AND RH FACTOR

SPECIMEN INFORMATION
Peripheral Blood Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result(s)

Blood Group (ABO typing)

"B"
(Manual hemagglutination)

RhD Factor (Rh Typing)

Positive
(Manual hemagglutination)

INTERPRETATION

The blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface
of red blood cells. Antibodies are found in plasma. To determine the blood group, red cells are mixed with different antibody
solutions to give A, B, O, or AB. The test is performed by both forward as well as reverse grouping methods.

Page 1 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:09 Hrs
Sample Processed At CORE GGN

TEST NAME
GLUCOSE RANDOM

SPECIMEN INFORMATION
Random Fluoride Plasma Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result Unit(s) Biological reference Interval

Glucose Random 77 mg/dL Non Diabetic : <200
((Enzymatic (Hexokinase/G-6-PDH)) Diabetic : >=200

COMMENTS

As per ADA Guidelines 2017, Diagnostic criteria for Diabetes: Random plasma glucose>/=200 mg/dL in a patient with classic
symptoms of hyperglycemia or hyperglycemic crisis.

Page 2 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:09 Hrs
Sample Processed At CORE GGN

TEST NAME
RPR, SERUM

SPECIMEN INFORMATION
Serum Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result(s)

RPR, serum
Non Reactive
(Slide Flocculation)

COMMENTS

1. A positive test indicates the presence of Syphilis reactive antibodies and a Negative or normal result
indicates an absence of antibodies reactive to Syphilis.
2. This is a screening test for syphilis. It is advisable to confirm the diagnosis by tests such as TPHA &
FTA-ABS.
3. VDRL (RPR) is useful for following the progression of disease and response to therapy.
4. Rising titers are of immense value in confirming the diagnosis.
5. Biological false-positive reactions usually exhibit low titers and may be seen in conditions like Viral
fevers, Mycoplasma infection, Chlamydia infection, Malaria, Immunizations, Pregnancy, Autoimmune
disorders, etc.
6. Test results must be interpreted in conjunction with the history, clinical and other laboratory findings of
the patient.
7. The laboratory performs RPR (Rapid Plasma Test), which uses the same antigen as VDRL, but the
antigen is bound to carbon particles to allow visualization of the reaction without a microscope.

Page 3 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 20/05/2023 , 15:33 Hrs
Sample Processed At SELF

TEST NAME
HAEMOGLOBIN ELECTROPHORESIS

SPECIMEN INFORMATION
Peripheral Blood Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result Unit(s) Biological reference Interval

Hb F <0.8 % 0.0-2.0
(High Performance Liquid Chromatography)

P3 4.5 Area %
(High Performance Liquid Chromatography)

Hb A1c - % <5.7
(High Performance Liquid Chromatography)

Hb A0 86.6 Area %
(High Performance Liquid Chromatography)

Hb A2 2.2 % 1.5-3.5
(High Performance Liquid Chromatography)

Unknown - %

HbS Absent Area % Absent

(High Performance Liquid Chromatography)

HbC Absent Area % Absent

(High Performance Liquid Chromatography)

HbD Absent Area % Absent

(High Performance Liquid Chromatography)

Haemoglobin (HB) 11.1 g/dL 12.0 to 15.0

(Photometry (Noncyanide Hemoglobin Analysis))

RBC Count 4.08 x10^6/uL 3.8 to 4.8

(DC Detection)

Hematocrit (HCT) 38.5 % 36 to 45

(RBC Pulse Height Detection)

MCV 94.4 fL 83 to 101

(DC Detection Method (Calculated))

MCH 27.2 pg 27 to 32
(DC Detection Method (Calculated))

Page 1 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 20/05/2023 , 15:33 Hrs
Sample Processed At SELF

MCHC 28.8 g/dL 31.50 to 34.50

(DC Detection Method (Calculated))

Red Cell Distribution Width (RDW-CV) 14.1 % 11.6 to 14.0

(DC Detection Method (Calculated))

IMPRESSIONS

There is no abnormal haemoglobin peak detected.

In antenatal cases, spouse screening should be done

COMMENTS

The Bio-Rad D-10 Hemoglobin testing system, βthalassemia Short Program provides an integrated method for the separation and
determination of the relative percentage of specific hemoglobin’s e.g. A2, F, abnormal hemoglobin (if present) in whole blood.
The separation is based on the principle of ion-exchange high-performance liquid chromatography. Confirmation of the status of
Hemoglobinopathies requires molecular diagnosis. Please note that the recent history of blood transfusion can change the
interpretation.
HbA2 value may be decreased in iron deficiency anemia; retesting should be performed after the iron deficiency is corrected. HbA2
value may be slightly elevated in megaloblastic anemia and HIV. HbA2 values greater than 10% should be tested for possible
presences of hemoglobin variant interference (HbS components, HbD, HbE). HbA2 values between 3.3% - 3.9% need careful
assessment along with family studies and the assay should be repeated after ruling out interfering factors on a fresh sample.
Borderline HbA2 values (3.6% - 4.0%) could result due to some mild Beta-thalassemia alleles or co- inheritance of delta
thalassemia. Some type of thalassemia trait has normal HbA2 values. HbA2 values for alpha thalassemia are usually low. For
pregnant females consider a testing partner. Some hemoglobin variants are clinically silent. Some Beta thalassemia mutant is
phenotypically silent, shows normal A2 values, and will not be detected on this screening assay.
This test does not detect the Alpha thalassemia trait condition.
Note: Hemoglobin HbA2 may be normal in some Beta thalassemia trait states e.g. silent beta thalassemia trait, Delta
beta-thalassemia, co inheritance of beta-thalassemia, alpha thalassemia trait, and iron deficiency anemia.
*Chromatogram enclosed
*Results relate only to the sample, as received.
GRAPH

Page 2 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 20/05/2023 , 15:33 Hrs
Sample Processed At SELF

Page 3 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:09 Hrs
Sample Processed At SELF

PANEL NAME
VIRAL MARKER PANEL

SPECIMEN INFORMATION
Serum Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

CLINICAL RESULT

HIV ANTIBODIES

Test Name Result(s)

HIV 1&2
Non Reactive
(Rapid Card)

COMMENTS

1. This is a screening test.

2. A Negative result implies that no Anti-HIV 1 or HIV 2 antibodies have been detected in the sample by this method. This means
that either the patient has not been exposed to HIV 1 or HIV 2 infection or the sample has been taken during the "WINDOW
PERIOD" (before the development of detectable levels of antibodies).
3. A PROVISIONALLY Positive result suggests the possibility of HIV 1 or HIV 2 infection.
4. To rule out false positivity, false negativity, and window period, kindly perform “Confirmatory Tests” like HIV by PCR.
5. As per the NACO guidelines on HIV testing, Strategy III has been adopted by CORE DIAGNOSTICS. The patient sample is
tested by three different methods/kits for all HIV provisionally reactive cases.

Page 1 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:09 Hrs
Sample Processed At SELF

TEST NAME
HEPATITIS B SURFACE ANTIGEN

CLINICAL RESULT

Test Name Result(s)

Hepatitis B Surface Antigen

Non Reactive
(Immunochromatography)

COMMENTS

1. The test should be used for the detection of HBsAg in serum or plasma only.
2. This is only a Screening test. All reactive samples should be confirmed by a confirmatory test. Therefore,
for a definitive diagnosis, the patient’s clinical history, symptomatology as well as serological data,
should be considered
3. False-positive results can be obtained due to the presence of other antigens or elevated levels of RF
factor. This occurs in less than 1% of the samples tested.

REFERENCES

1. Blumberg, B.S., (1964) Bull. N.Y. Acab Med., 40:377

2. Blumberg B.S. etal, (1965) J.A.M.A. 191:541.
3. Caldwell C.W. etal., (1977) Clin. Chem. Acta: 31:305.
4. Peterson, D.L. etal., (1982) J. Biol. Chem., 257(17): 10414

Page 2 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:09 Hrs
Sample Processed At SELF

TEST NAME
HCV ANTI HEPATITIS C VIRUS (HCV)

CLINICAL RESULT

Test Name Result(s)

Anti Hepatitis C Virus (HCV)

Non Reactive
(Immunochromatography)

COMMENTS

1. The HCV TRI-DOT detects anti-HCV in human serum or plasma and is only a screening test.
2. All reactive samples should be confirmed by confirmatory test. Therefore for a definitive diagnosis, the patient’s clinical
history, symptomatology as well as serological data, should be considered.
3. All weakly reactive samples need further clinical correlation and are advised repeat anti-HCV serology testing after 4 to 6
weeks. A confirmatory test i.e., HCV RNA Quantitative Real-time PCR & HCV Genotyping (if, clinically indicated), is also
advised.
4. A non-reactive result does not exclude the possibility of exposure to or infection with HCV.
5. It should be noted that repeated false reactive results may occur due to non-specific binding of the sample to the membrane.
6. The presence of anti-HCV does not imply a Hepatitis C infection but may be indicative of recent and / or past infection by HCV.
7. Patients with auto-immune liver diseases, Renal disorders and Antenatal samples may show false reactive results.

REFERENCES

• Caypers, H.T.M. Wiakel, I.N. Vander Poel, C.L. etal (1971) J. of Hepatology, 13, 5.15.
• Halfon, P. etal (1997) J. Medical Virology. 52:391-395.
• Sarin, S.K. & Hess. G. (1998). Transfusion associated Hepatitis.
• Sayers, M.H. & Gretch D.R. (1993). J. Transfusion 30,809-13

Page 3 of 3
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 20/05/2023 , 19:35 Hrs
Sample Processed At SELF

PANEL NAME
TORCH PANEL, IGM

SPECIMEN INFORMATION
Serum Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result Unit(s) Biological reference Interval

Toxoplasma - IgM 0.12 Index Non Reactive: < 0.5
(Chemiluminescent microparticle immunoassay (CMIA)) Grey Zone: 0.5-0.59
Reactive: >= 0.6
Rubella (German Measles) - IgM 0.23 Index Negative: <1.2
(Chemiluminescent microparticle immunoassay (CMIA)) Equivocal: >=1.2-<1.6
Positive: >=1.6

Cytomegalo Virus (CMV) - IgM 0.23 Index Nonreactive: <0.85

(Chemiluminescent microparticle immunoassay (CMIA)) Reactive: ≥1.00
Herpes Simplex Virus (HSV) 1 & 2 - IgM 0.60 Index Negative: < 0.9
(Enzyme Linked Immunosorbent Assay (ELISA)) Equivocal: 0.9-1.1
Positive: >1.1

INTERPRETATION

The TORCH test is used to screen pregnant women and newborns for antibodies to the infectious diseases
included in the panel if either the mother or newborn has symptoms. The blood test can determine if the
person has had a recent infection, a past infection, or has never been exposed.
The test is ordered when a pregnant woman is suspected of having any of the TORCH infections.
These infections can be serious if they occur during pregnancy because they can cross the placenta from
the mother to the developing fetus and can cause congenital defects in the newborn.
Rubella infection during the first 16 weeks of pregnancy presents major risks for the unborn baby.
When a pregnant woman has a rash and other symptoms of rubella, laboratory tests are required to make
the diagnosis. A physician cannot tell if a person has rubella by their clinical appearance since other
infections may look the same. Women infected with Toxoplasma or CMV may have flu-like symptoms that
are not easily differentiated from other illnesses.
Antibody testing will help the physician diagnose an infection that may be harmful to the unborn baby. The
test may be ordered on the newborn when the infant shows any signs suggestive of these infections, such
as Exceptionally small size relative to the gestational age, Deafness, Mental retardation, Seizures, Heart

Page 1 of 2
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 20/05/2023 , 19:35 Hrs
Sample Processed At SELF

defects Cataracts, enlarged liver or spleen, Low platelet level, or Jaundice Results are usually given as
positive or negative, indicating the presence or absence of IgG and IgM antibodies for each of the
infectious agents tested for with the panel. A normal result is a negative (undetectable) IgM antibody in the
blood of the mother or newborn.
The presence of IgM antibodies indicates either a current or recent infection. A positive IgM result in a
newborn indicates a high likelihood of infection with that organism. IgM antibodies produced in the mother
cannot cross the placenta, so the presence of this type of antibody strongly suggests an active infection in
the infant. The presence of IgG and absence of IgM antibody in an infant may reflect passive transfer of
maternal antibody to the baby and does not indicate an active infection in that infant.
Likewise, the presence of IgM antibodies in a pregnant woman suggests a new infection with the virus or
parasite. Further testing must be done to confirm these results since IgM antibodies may be present for
other reasons.
IgG antibodies in the pregnant woman may be a sign of past infection with one of these infectious agents.
By testing a second blood sample drawn two weeks later, the level of antibody can be compared.
If the second blood draw shows an increase in IgG antibody, it may indicate a recent infection with the
infectious agent

Page 2 of 2
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:39 Hrs
Sample Processed At SELF

PANEL NAME
KIDNEY FUNCTION TEST

SPECIMEN INFORMATION
Serum Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result Unit(s) Biological reference Interval

Blood Urea Nitrogen (BUN) 11.18 mg/dL 7.0-18.7
(Urease)

Creatinine 0.73 mg/dL 0.57-1.11

(Kinetic Alkaline Picrate)

Uric Acid 3.4 mg/dL 2.6-6.0

(Uricase)

Calcium 10.2 mg/dL 8.4-10.2

(Arsenazo III)

Sodium 134.9 mmol/L 135.0-150.0

(Ion Selective Electrodes Direct)

Potassium 4.32 mmol/L 3.5-5.0

(Ion Selective Electrodes Direct)

Chloride 91.9 mmol/L 94-110

(Ion Selective Electrodes Direct)

COMMENTS

1. Causes of increased levels of BUN: a ) Pre renal: High protein diet, Increased protein cataolism, GI hemorrhage, Cortisol,
Dehydration, CHF Renal b) Renal: Renal Failure c) Post Renal: Malignancy, Nephrolithiasis, Prostatism.
2. Creatinine higher than normal level may be due to: Blockage in the urinary tract, Kidney problems such as kidney damage,
failure, infection, reduced blood flow; Loss of body fluid (dehydration); Muscle problems such as breakdown of muscle fibers;
Problems during pregnancy such as seizures (eclampsia) or high blood pressure caused by pregnancy (preeclampsia).
3. Serum uric acid levels are increased in gout, renal failure, inherited metabolic disorders, excess dietary purine intake, increased
nucleic acid turnover (e.g. leukemia, myeloma, radiotherapy, chemotherapy, trauma), psoriasis, preeclampsia and alcohol
consumption.
4. Electrolytes (Na, K and Cl ) play an important role in water homeostasis, maintenance of pH, regulation of heart and muscle
function, as well as act as co-factors for enzymes. The kidneys help to maintain electrolyte concentrations by regulating their
concentrations in the body.

Page 1 of 2
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 16:39 Hrs
Sample Processed At SELF

Page 2 of 2
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 14:46 Hrs
Sample Processed At SELF

PANEL NAME
LIVER FUNCTION TEST

SPECIMEN INFORMATION
Serum Collected on 18/05/2023 , 20:00 Hrs

CLINICAL HISTORY
HPLC Checklist Received

RESULT

Test Name Result Unit(s) Biological reference Interval

Total Protein 7.1 g/dL 6.4-8.3
(Biuret)

Albumin 4.2 g/dL 3.5-5.2

(Colorimetric (Bromcresol Green))

Globulin 2.9 g/dL 2.5-3.5

(Calculated)

A/G Ratio 1.45 Ratio 1.0-2.0

(Calculated)

Bilirubin, Total 0.37 mg/dL 0.3-1.2

(Spectrophotometry (Diazonium salt))

Bilirubin Direct 0.16 mg/dL 0.0-0.5

(Diazo Reaction)

Bilirubin Indirect 0.21 mg/dL 0.2-1.2

(Calculated)

Aspartate Aminotransferase (AST) 19 U/L 5.0-34.0

(Enzymatic (NADH [without P-5'-P]))

Alanine Aminotransferase (ALT) 16 U/L 0.0-55.0

(Enzymatic (NADH [without P-5'-P]))

Alkaline Phosphatase (ALP) 55 U/L 40.0-150.0

(Para-nitrophenyl Phosphate)

Gamma-Glutamyl Transferase (GGT) 13 U/L 9.0-36.0

(L-Gamma-glutamyl-3-carboxy-4-nitroanilide Substrate)

Page 1 of 2
 Case ID 103230037621
Patient Name VINEETA DHILLON
Age/Sex 42 years / Female
Hospital Location
Hospital Name Khandelwal Clinic, Delhi
Physician Name Dr. Reena Khandelwal
Date & Time of Accessioning 19/05/2023 , 13:04 Hrs
Date & Time of Reporting 19/05/2023 , 14:46 Hrs
Sample Processed At SELF

COMMENTS

1. Increased AST: Primary liver disease, acute myocardial infarction, muscle trauma and diseases, pancreatitis,
intestinal surgery, burns, renal infarction, pulmonary embolism
2. Increased ALT: Primary liver disease, biliary obstruction, pancreatitis.
3. Increased ALP: Biliary obstruction, primary liver disease (changes parallel GGT), infiltrative liver disease, bone
diseases, hyperparathyroidism, hyperthyroidism
4. Increased GGT: Biliary obstruction, primary liver disease (changes parallel ALP), alcohol consumption,
pancreatitis
5. Increased Bilirubin: Biliary obstruction, primary liver disease, hemolytic anemia, hypothyroidism, malignancy

Page 2 of 2
 Question?
Contact us at +91 124 4615 615
Toll Free Helpline +91 8882899999

CONDITIONS OF REPORTING
1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the
bill/test request form.

2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transport-
ed per specific instructions given by the physicians/laboratory.

3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.

4. Some tests are referred to other laboratories to provide a wider test menu to the customer.

5. Core Diagnostics Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruction of specimen, which is not
attributable to any direct and mala fide act or omission of Core Diagnostics Pvt. Ltd. or its employees. Liability of Core Diag-
nostics Pvt. Ltd. for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the rele-
vant laboratory services.

This report is the property of CORE Diagnostics. The information contained in this report is strictly confidential and is only for

the use of those authorized. If you have received this report by mistake, please contact CORE Diagnostics

CORE Diagnostics (Central Reference Lab) - Gurugram

406, Udyog Vihar, Phase III, Gurugram-122016

CORE Diagnostics Lab - New Delhi CORE Diagnostics Lab - Bangalore

C-13, 1st Floor, Green Park Extension, New Delhi-110016 1st Floor, KMK Tower, 142 KH Road, Bangalore-560027

CORE Diagnostics Lab - Lucknow CORE Diagnostics Lab - Bhubaneswar

J.S. Tower, Plot No. K-702, Sector-K, Ashiyana, Plot No. 249, Near Police Academy, AIIMS Nagar,
Near Raj Luxmi Sweets, Lucknow-226012 Patrapada, Bhubaneswar-751019

Page 2 of 3